European neurological review最新文献_第4页

Charles Bonnet Syndrome as a Rare Complication in an Ischaemic Stroke Charles Bonnet综合征是缺血性中风中一种罕见的并发症

European neurological review Pub Date : 2018-01-01 DOI: 10.17925/ENR.2018.13.2.120

H. Santos, Pedro Agrela, C. Parente, Kelly Lopes, S. Santos, A. Cardoso, F. Campante

引用次数: 1

Prevalence and pattern of craniofacial pain and headache in Danish patients with neuromyelitis optica spectrum disorder 丹麦视神经脊髓炎患者颅面疼痛和头痛的患病率和类型

European neurological review Pub Date : 2018-01-01 DOI: 10.17925/ENR.2018.13.1.44

Gebbie A. R. Nielsen, H. H. Nielsen, Z. Illés, P. Gazerani

引用次数: 0

Cognitive Assessment in Multiple Sclerosis 多发性硬化症的认知评估

European neurological review Pub Date : 2018-01-01 DOI: 10.17925/ENR.2018.13.1.12

D. Langdon

引用次数: 0

Refractory Myasthenia Gravis – Patient Burden and the Need for New Therapeutic Targets 难治性重症肌无力-患者负担和对新治疗靶点的需求

European neurological review Pub Date : 2018-01-01 DOI: 10.17925/ENR.2018.13.1.18

S. Jacob

引用次数: 2

Sphingosine-1-phosphate Receptor Modulators in Multiple Sclerosis 多发性硬化症中的鞘氨醇-1-磷酸受体调节剂

European neurological review Pub Date : 2018-01-01 DOI: 10.17925/ENR.2018.13.1.25

P. Vermersch

引用次数: 2

Management of Migraine and the Accessibility of Specialist Care – Findings from a Multi-national Assessment of 28 Healthcare Networks 偏头痛的管理和专科护理的可及性——来自28个医疗保健网络的多国评估结果

European neurological review Pub Date : 2018-01-01 DOI: 10.17925/ENR.2018.13.2.103

Pinay Kainth, N. Murphy, S. Rossi, Jean-Noël Talabardon, M. Pedrazzoli, Leonardo Mascagni, Irene Menarini, Dublin Ireland Novartis Ireland Limited, Basel Switzerland Novartis Pharma Ag

{"title":"Management of Migraine and the Accessibility of Specialist Care – Findings from a Multi-national Assessment of 28 Healthcare Networks","authors":"Pinay Kainth, N. Murphy, S. Rossi, Jean-Noël Talabardon, M. Pedrazzoli, Leonardo Mascagni, Irene Menarini, Dublin Ireland Novartis Ireland Limited, Basel Switzerland Novartis Pharma Ag","doi":"10.17925/ENR.2018.13.2.103","DOIUrl":"https://doi.org/10.17925/ENR.2018.13.2.103","url":null,"abstract":"Introduction: Migraine is one of the leading reasons for patient access to neurology services. Waiting lists can limit patients’ ability to access specialist care, even at specialised headache centres. Our study aims to investigate this issue, identify possible root causes and also document existing good practices. Methods: We conducted a study in a sample of 28 headache centres and their networks in six countries by performing in-depth interviews with 166 healthcare professionals. Results: The waiting list for new patients and follow-up visits exceeded 3 months in 61% and 36% of centres, respectively. Patients waited on average 6 months for their first consultation, with peaks beyond 12 months. Five areas were identified as common root causes: (1) inappropriate referral of patients with low-frequency episodic migraine or patients under acute treatment, (2) lack of triage/priority allocation, (3) limited resource availability or resources dedicated to migraine, (4) limited delegation of activities, and (5) suboptimal management of follow-up visits. Conclusion: Our work highlights a gap between best practices for migraine management proposed in the literature and current real-world practice. Guidelines recommend a “network” approach to bridge different levels of care. Based on our findings, consistency in practice amongst specialised headache clinics and integration with primary care represent an important area for further improvement.","PeriodicalId":12047,"journal":{"name":"European neurological review","volume":"13 1","pages":"103"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67592220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Residential Care for People with Dementia in Europe – Not the Same Policy Standards Everywhere 欧洲痴呆症患者的住院护理-各地的政策标准不同

European neurological review Pub Date : 2018-01-01 DOI: 10.17925/ENR.2018.13.1.14

A. Diaz-Ponce, J. Georges

引用次数: 0

Cerebrovascular Lesions in Alzheimer-associated Diseases – A Neuropathological Study with 7.0-tesla Magnetic Resonance Imaging 阿尔茨海默病相关疾病的脑血管病变- 7.0特斯拉磁共振成像的神经病理学研究

European neurological review Pub Date : 2018-01-01 DOI: 10.17925/ENR.2018.13.2.100

J. Reuck, Degenerative

{"title":"Cerebrovascular Lesions in Alzheimer-associated Diseases – A Neuropathological Study with 7.0-tesla Magnetic Resonance Imaging","authors":"J. Reuck, Degenerative","doi":"10.17925/ENR.2018.13.2.100","DOIUrl":"https://doi.org/10.17925/ENR.2018.13.2.100","url":null,"abstract":"Mixed dementias are clinically under-recognised and need neuropathological confirmation. The most frequent types are those composed of Alzheimer’s dementia (AD) associated with cerebral amyloid angiopathy (CAA), cerebral arteriosclerotic micro-angiopathy (CAMA) and Lewy body disease (LBD). The present neuropathological study with 7.0-tesla magnetic resonance imaging (MRI) compares the impact and the distribution of cerebrovascular lesions between unmixed AD brains to those with different types of associated disorders. Twenty-six unmixed AD brains were compared to 12 associated with LBD, eight with CAMA and 24 with CAA. On neuropathological examination brains with AD-CAA had the most severe cerebrovascular lesions, those with AD-CAMA had a higher number of lacunes and in the AD-LBD brains only an increase of cortical micro-infarcts was observed. On MRI examination, white matter changes were only increased in the AD-CAA group. Cortical micro-infarcts were significantly more frequent in all the sections of the AD-CAA and AD-CAMA groups. In the AD-LBD brains, they were only moderately more common in the occipital section. Cortical micro-bleeds were observed in all mixed dementia cases. A moderate amount of superficial siderosis was only seen in the AD-CAA brains. The present study confirms our previous findings that CAA and CAMA are the main causes of occurrence of different cerebrovascular lesions in the mixed AD brains.","PeriodicalId":12047,"journal":{"name":"European neurological review","volume":"13 1","pages":"100"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67592215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acute Kidney Injury and Creatine Kinase Elevation After Beginning Treatment with Levetiracetam 左乙拉西坦开始治疗后急性肾损伤和肌酸激酶升高

European neurological review Pub Date : 2018-01-01 DOI: 10.17925/ENR.2018.13.2.113

F. Mena-Martín, A. Gutiérrez-García, J. Martín‐Escudero, O. Fernández-Arconada

{"title":"Acute Kidney Injury and Creatine Kinase Elevation After Beginning Treatment with Levetiracetam","authors":"F. Mena-Martín, A. Gutiérrez-García, J. Martín‐Escudero, O. Fernández-Arconada","doi":"10.17925/ENR.2018.13.2.113","DOIUrl":"https://doi.org/10.17925/ENR.2018.13.2.113","url":null,"abstract":"L evetiracetam (LEV) is one of the most common anti-epileptic drugs available. In general, it is tolerated relatively well; the majority of adverse effects are moderate and normally occur during the initial titration. We present a patient who developed two moderately serious adverse effects after an initial LEV dose: a 28-year-old male was admitted to intensive care unit after suffering two generalised seizures, and was given 1000 mg of LEV. Twenty-four hours after admittance, the laboratory tests showed a serum creatinine of 2.84 mg/dL and creatine kinase (CK) of 421 U/L (normal, 0–171 U/L). At all times the diuresis was normal, with a maximum value of creatinine of 4.67 mg/dL 48 hours following admittance, and the CK values ranged between 421–681 U/L with proteinuria of 840 mg/day. On the seventh day, blood tests showed a CK of 1,559 U/L and a creatinine of 1.55 mg/dL. LEV was progressively substituted for lacosamide, after which creatinine, CK and albumin excretion rate were normalised. Thus, CK and renal function during treatment with LEV should be monitored, and acute kidney injury due to LEV should be considered in the differential diagnosis for any unexplained acute renal failure.","PeriodicalId":12047,"journal":{"name":"European neurological review","volume":"13 1","pages":"113"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67592229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

New Insights into Cluster Headache 丛集性头痛的新见解

European neurological review Pub Date : 2018-01-01 DOI: 10.17925/ENR.2018.13.2.68

N. Lund

引用次数: 0